
# Clinical Pharmacology Summary – ADA Drug Interference & PandA Correction

**Product:** Monoclonal X • **Sponsor:** Demo Biotech • **Date:** 2025-10-25

## 1. Bioanalytical Methods & Interference
PandA (PEG + Acid) improves drug tolerance vs standard bridging (≥80% recovery up to ≥100 µg/mL).

![Drug tolerance](/Users/cmontefusco/Coding projects/regulatory-style-clinpharm-report/output/figures/recovery_overlay_sim_vs_lit.png)

**PASS/ALERT summary**

![PASS/ALERT table](/Users/cmontefusco/Coding projects/regulatory-style-clinpharm-report/output/figures/pass_alert_table.png)

## 2. Population PK & Variability (brief)
At Week 52, ADA⁺ subjects show reduced troughs.

![Week-52 troughs by detected ADA](/Users/cmontefusco/Coding projects/regulatory-style-clinpharm-report/output/figures/wk52_by_detected_ADA_assay.png)

## 3. Exposure–Response & Target Attainment
True exposure–response shows reduced efficacy at low troughs.

![True exposure–response](/Users/cmontefusco/Coding projects/regulatory-style-clinpharm-report/output/figures/exposure_response_true.png)

Target attainment table (CSV): `/Users/cmontefusco/Coding projects/regulatory-style-clinpharm-report/output/TLG_target_attainment.csv`

## 4. Dose Recommendation (draft)
Use **PandA-based immunogenicity** for PK/E–R decisions at therapeutic drug levels.
If program requires ≥X% target attainment, consider dose adjustment **only if** safety margin allows.

## 5. Conclusions
- Standard bridging fails tolerance benchmark; PandA passes.
- Bioanalytical method selection materially changes PK/E–R interpretation and dose justification.